News

New investor Deerfield Management Company led the financing, which also included participation from new investor Casdin Capital as well as existing investors Fidelity Management and Research Company, WuXi

These tests will be used to help identify patients for MedImmune’s MEDI4893 and MEDI3902 clinical programs, which are being conducted within the COMBACTE consortium to explore the use

ThromboGenics hopes to be able to reduce the risk of disease progression to proliferative diabetic retinopathy (PDR) by inducing a total PVD using ocriplasmin. PDR is the major

The EORTC intergroup trial 1206:"A randomised phase II study to evaluate the efficacy and safety of chemotherapy vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic,

The MHRA conducted a site-specific inspection in November 2015 to evaluate whether the Group’s existing manufacturing processes and quality management systems had been effectively extended and implemented at

The deal is anticipated to close by the end of this month, earlier than scheduled. Galapagos will receive an upfront payment of $725m, which includes a license fee

The drug is being developed by Ionis Pharmaceuticals and GSK. The companies are also collaborating on the development of IONIS-HBV Rx, a generation 2.0+ antisense HBV drug. Ionis

VAL-083 is a small-molecule chemotherapeutic, which is indicated to treat glioblastoma multiforme (GBM), the most common and deadly cancer that starts within the brain. Under the collaboration, MD

CASI’s China rights to MARQIBO was licensed from its partner Spectrum Pharmaceuticals, Inc. MARQIBO is the first and only liposome-encapsulated vincristine approved and currently marketed in the U.S.